Corticosteroids in rheumatoid arthritis

doi:10.1016/0049-0172(89)90083-8

Seminars in Arthritis and Rheumatism

Volume 19, Issue 1, August 1989, Pages 9-21

https://doi.org/10.1016/0049-0172(89)90083-8 Get rights and content

Abstract

This report has presented evidence to support a disease-modifying role for corticosteroids in rheumatoid arthritis. It would appear that the efficacy of these agents in retarding the destructive course of rheumatoid disease has been substantially underestimated. Consideration for more liberal use of corticosteroids in the management of rheumatoid arthritis is warranted. Further study on new approaches to corticosteroid delivery is proposed.

References (74)

R Million et al.
Long-term study of management of rheumatoid arthritis
Lancet
(1984)
JR Kirwan et al.
Rheumatoid arthritis: Disease-modifying anti-rheumatic drugs
Clin Rheum Dis
(1983)
TL Gerrard et al.
Hydrocortisone-mediated inhibition of monocyte antigen presentation: Dissociation of inhibitory effect and expression of DR antigens
Cell Immunol
(1984)
L Stavy et al.
The effect of hydrocortisone on lymphocyte-mediated cytolysis
Cell Immunol
(1973)
F Hirata
The regulation of lipomodulin, a phospholipase inhibitory protein, in rabbit neutrophils by phosphorylation
J Biol Chem
(1981)
JE Lehmeyer et al.
Effect of antiinflammatory drugs and agents that elevate cyclic AMP on the release of toxic oxygen metabolites by phagocytes
Clin Immunol Immunopathol
(1978)
DS David et al.
Adrenal glucocorticoids after twenty years
J Chron Dis
(1970)
DT Felson et al.
A cross-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone
Lancet
(1987)
RG Gray et al.
Local corticosteroid injection treatment in rheumatic disorders
IR Reid et al.
Prevention of steroid-induced osteoporosis with (3-amino-1 hydroxypropylidene)-1,1, bisphosphonate (APD)
Lancet
(1988)

DJ Nashel

Is atherosclerosis a complication of long term corticosteroid treatment?

Am J Med

(1986)

MH Lepper

Prophylaxis in patients receiving adrenal steroid therapy

J Chron Dis

(1962)

RC Urban et al.

Corticosteroid induced cataracts

Surv Ophthalmol

(1986)

G Gregoriadis et al.

Drugcarrier potential of liposomes in cancer chemotherapy

Lancet

(1974)

M DeSilva et al.

Liposomes in arthritis: A new approach

Lancet

(1979)

PE Lipsky

Rheumatoid arthritis

S Ruddy

The management of rheumatoid arthritis

Arthritis Foundation

Rheumatoid arthritis

PS Hench

The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone

Ann Intern Med

(1952)

EC Kendall

Some observations on the hormone of the adrenal cortex designated compound E

WD Robinson

Rheumatism and arthritis

Ann Intern Med

(1953)

RW Lightfoot

The treatment of rheumatoid arthritis

Joint Committee of the Medical Research Council and Nuffield Foundation

A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis

Br Med J

(1954)

Empire Rheumatism Council

Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis

Ann Rheum Dis

(1955)

Joint Committee of the Medical Research Council and Nuffield Foundation

A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis

Ann Rheum Dis

(1959)

Joint Committee of the Medical Research Council and Nuffield Foundation

A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis

Ann Rheum Dis

(1960)

L Iannuzzi et al.

Does drug therapy slow radiographic deterioration in rheumatoid arthritis?

N Engl J Med

(1983)

CA Berntsen et al.

Rheumatoid patients after five or more years of corticosteroid treatment: A comparative analysis of 183 cases

Ann Intern Med

(1961)

HF West

Rheumatoid arthritis: The relevance of clinical knowledge to research activities

Abstr World Med

(1967)

ED Harris et al.

Low dose prednisone therapy in rheumatoid arthritis: A double blind study

J Rheumatol

(1983)

MR Liebling et al.

Pulse methylprednisolone in rheumatoid arthritis

Ann Intern Med

(1981)

Empire Rheumatism Council

Gold therapy in rheumatoid arthritis: Report of a multi-centre controlled trial

Ann Rheum Dis

(1960)

JW Sigler et al.

Gold salts in the treatment of rheumatoid arthritis

Ann Intern Med

(1974)

R Luukkainen et al.

Effects of gold treatment on the progression of erosions in rheumatoid arthritis patients

Scand J Rheum

(1977)

JE Parrillo et al.

Mechanisms of glucocorticoid action on immune processes

Annu Rev Pharmacol Toxicol

(1979)

RH Ebert et al.

Changes in connective tissue reaction induced by cortisone

Ann Intern Med

(1952)

DH Nelson

Corticosteroid-induced changes in phospholipid membranes as mediators of their action

Endocr Rev

(1980)

Cited by (61)

Nrf2 activation improves experimental rheumatoid arthritis
2023, Free Radical Biology and Medicine
Rheumatoid arthritis is a systemic autoimmune disease with pain and functional disorder of joints. Multiple strategies toward treatment of the rheumatoid arthritis are operating, while there are concerns of serious adverse effects of the therapeutic drugs. Here, we show that activation of Nrf2 (Nuclear factor erythroid 2-related factor 2) efficiently improves arthritis of SKG mice, which develop T cell-mediated autoimmune arthritis by zymosan A injection. We found that genetic Nrf2 activation by knockdown of Keap1 (Kelch-like ECH-associated protein 1), a negative regulator of Nrf2, repressed arthritis by inhibiting the expression of pro-inflammatory cytokines and inducing the expression of antioxidant enzymes in SKG mice. In addition, oral administration of CDDO-Im, a representative chemical inducer of Nrf2, had effects of both prevention and treatment toward arthritis of SKG mice in an Nrf2-dependent manner. We also found that Nrf2 activation through myeloid-cell lineage-specific Keap1 disruption did not achieve significant improvement in the arthritis of SKG mice. In contrast, expressions of pro-inflammatory cytokine genes were decreased, and those of antioxidant enzyme genes were increased in fibroblast-like synoviocytes (FLS) isolated from SKG mouse. Our results thus demonstrate that Nrf2 activation exerts marked anti-arthritis effects in the SKG experimental rheumatoid arthritis model mice, supporting the contention that the Nrf2 activation is a new therapeutic strategy for the rheumatoid arthritis.
Injectable PLGA/hydrocortisone formulation produced by continuous supercritical emulsion extraction
2013, International Journal of Pharmaceutics
Citation Excerpt :
Osteoarthritis usually involves one joint; while, rheumatoid arthritis normally attacks multiple joints as well as some organs. Conventional treatment of OA and RA includes intra-articular administration of glucocorticoids (Weiss, 1989); it has been recommended to reduce complications of oral administration and has been proved to produce symptomatic relief in joint inflammation. However, the systemic application is limited, due to a high incidence of serious side effects, especially related to long-term treatment; therefore, sustained release via carrier formulations can be significant to avoid the adverse effects and prolong the retaining time of the drug in the articular cavity over a period of some weeks.
The objective of the present study was to develop an anti-inflammatory prolonged action formulation for local injection in prefilled syringes. Hydrocortisone acetate (HA) was selected as a model corticosteroid drug to be incorporated in poly(lactic-co-glycolic) (PLGA) microspheres. The formulation was obtained by supercritical emulsion extraction in continuous operation layout (SEE-C) to test the process robustness for a continuous industrial production. PLGA/HA microspheres with mean sizes between 1 μm (SD ± 0.20) and 5 μm (SD ± 1.45) were obtained when operating at 80 bar and 38 °C with a L/G ratio of 0.1 in the counter-current tower. The produced microdevices showed excellent encapsulation efficiencies between 75% and 80%, depending on the emulsion formulations tested, and different sustained release in the range of 6–15 days. In dependence of the different emulsion (single or double) processed by SEE-C, different products can be obtained according to the therapeutic requests. SEE-C confirms to be an innovative and flexible technology for biopolymer microdevices production, coupling the efficiency of continuous operation to the easy process scalability.
Arthroscopic synovectomy versus intra-articular injection of corticosteroids for the management of refractory psoriatic or rheumatoid arthritis of the wrist: study protocol for a randomized controlled trial (ARCTIC trial)
2023, Trials
In vivo quantitative photoacoustic monitoring of corticosteroid-induced vasoconstriction
2023, Journal of Biomedical Optics
Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: An overview of systematic reviews
2021, RMD Open
Point-of-care musculoskeletal ultrasound is critical for the diagnosis of hemarthroses, inflammation and soft tissue abnormalities in adult patients with painful haemophilic arthropathy
2015, Haemophilia

View all citing articles on Scopus

¹: From the Division of Rheumatology, Southern California Permanente Medical Group.

View full text

Corticosteroids in rheumatoid arthritis

Abstract

Lancet

Clin Rheum Dis

Cell Immunol

Cell Immunol

J Biol Chem

Clin Immunol Immunopathol

J Chron Dis

Lancet

Lancet

Am J Med

J Chron Dis

Surv Ophthalmol

Lancet

Lancet

Rheumatoid arthritis

The management of rheumatoid arthritis

Rheumatoid arthritis

The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone

Ann Intern Med

Some observations on the hormone of the adrenal cortex designated compound E

Rheumatism and arthritis

Ann Intern Med

The treatment of rheumatoid arthritis

A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis

Br Med J

Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis

Ann Rheum Dis

A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis

Ann Rheum Dis

A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis

Ann Rheum Dis

Does drug therapy slow radiographic deterioration in rheumatoid arthritis?

N Engl J Med

Rheumatoid patients after five or more years of corticosteroid treatment: A comparative analysis of 183 cases

Ann Intern Med

Rheumatoid arthritis: The relevance of clinical knowledge to research activities

Abstr World Med

Low dose prednisone therapy in rheumatoid arthritis: A double blind study

J Rheumatol

Pulse methylprednisolone in rheumatoid arthritis

Ann Intern Med

Gold therapy in rheumatoid arthritis: Report of a multi-centre controlled trial

Ann Rheum Dis

Gold salts in the treatment of rheumatoid arthritis

Ann Intern Med

Effects of gold treatment on the progression of erosions in rheumatoid arthritis patients

Scand J Rheum

Mechanisms of glucocorticoid action on immune processes

Annu Rev Pharmacol Toxicol

Changes in connective tissue reaction induced by cortisone

Ann Intern Med

Corticosteroid-induced changes in phospholipid membranes as mediators of their action

Endocr Rev